TY - JOUR
T1 - Development of a ‘ready-to-use’ tool that includes preventability, for the assessment of adverse drug events in oncology
AU - the IATRIGGER Working Group
AU - Hébert, Guillaume
AU - Netzer, Florence
AU - Kouakou, Sylvain Landry
AU - Lemare, François
AU - Minvielle, Etienne
AU - Assaf, Elias
AU - Bardin, Christophe
AU - Basuyau, Florence
AU - Bedouch, Pierrick
AU - Charlety, Dominique
AU - Contentin, Nathalie
AU - Daouphars, Mikael
AU - Di Fiore, Frédéric
AU - Doucet, Ludovic
AU - Guillemet, Cécile
AU - Joly, Anne Chrisitine
AU - Joly, Charlotte
AU - Le Bras, Fabien
AU - Leheurteur, Marianne
AU - Lottin, Marion
AU - Lucas, Mélodie
AU - Madelaine, Isabelle
AU - Merle, Véronique
AU - Pons-Kerjean, Nathalie
AU - Remon-Masip, Jordi
AU - Rousseau, Benoit
AU - Rouvet, Jean
AU - Saldana, Caroline
AU - Slimano, Florian
AU - Toffart, Anne Claire
AU - Tournigand, Christophe
AU - Varin, Remi
AU - Vekhoff, Anne
AU - Verlinde-Carvalho, Muriel
N1 - Publisher Copyright:
© 2018, Springer International Publishing AG.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background Adverse drug events (ADEs) occur frequently in oncology and justify continuous assessment and monitoring. There are several methods for detecting them, but the trigger tool method seems the most appropriate. Although a generic tool exists, its use for ADEs in oncology has not been convincing. The development of a focused version is therefore necessary. Objective To provide an oncology-focused trigger tool that evaluates the prevalence, harm, and preventability in a standardised method for pragmatic use in ADE surveillance. Setting Hospitals with cancer care in France. Method The tool has been constructed in two steps: (1) constitution of an oncology-centred list of ADEs; 30 pharmacists/practitioners in cancer care from nine hospitals selected a list of ADEs using a method of agreement adapted from the RAND/UCLA Appropriateness Method; and (2) construction of three standardised dimensions for the characterisation of each ADE (including causality, severity, and preventability). Main outcome measure The main outcome measure was validation of the tool, including preventability criteria. Results The tool is composed of a final list of 15 ADEs. For each ADE, a ‘reviewer form’ has been designed and validated by the panel. It comprises (1) the trigger(s), (2) flowcharts to guide the reviewer, (3) criteria for grading harm, and (4) a standardised assessment of preventability with 6–14 closed sentences for each ADE in terms of therapeutic management and/or prevention of side-effects. Conclusion A complete ‘ready-to-use’ tool for ADE monitoring in oncology has been developed that allows the assessment of three standardised dimensions.
AB - Background Adverse drug events (ADEs) occur frequently in oncology and justify continuous assessment and monitoring. There are several methods for detecting them, but the trigger tool method seems the most appropriate. Although a generic tool exists, its use for ADEs in oncology has not been convincing. The development of a focused version is therefore necessary. Objective To provide an oncology-focused trigger tool that evaluates the prevalence, harm, and preventability in a standardised method for pragmatic use in ADE surveillance. Setting Hospitals with cancer care in France. Method The tool has been constructed in two steps: (1) constitution of an oncology-centred list of ADEs; 30 pharmacists/practitioners in cancer care from nine hospitals selected a list of ADEs using a method of agreement adapted from the RAND/UCLA Appropriateness Method; and (2) construction of three standardised dimensions for the characterisation of each ADE (including causality, severity, and preventability). Main outcome measure The main outcome measure was validation of the tool, including preventability criteria. Results The tool is composed of a final list of 15 ADEs. For each ADE, a ‘reviewer form’ has been designed and validated by the panel. It comprises (1) the trigger(s), (2) flowcharts to guide the reviewer, (3) criteria for grading harm, and (4) a standardised assessment of preventability with 6–14 closed sentences for each ADE in terms of therapeutic management and/or prevention of side-effects. Conclusion A complete ‘ready-to-use’ tool for ADE monitoring in oncology has been developed that allows the assessment of three standardised dimensions.
KW - Adverse drug event
KW - France
KW - Healthcare quality
KW - Oncology
KW - Patient cancer care
KW - Preventability
KW - Trigger tool
UR - http://www.scopus.com/inward/record.url?scp=85042098516&partnerID=8YFLogxK
U2 - 10.1007/s11096-017-0542-3
DO - 10.1007/s11096-017-0542-3
M3 - Article
C2 - 29446003
AN - SCOPUS:85042098516
SN - 2210-7703
VL - 40
SP - 376
EP - 385
JO - International Journal of Clinical Pharmacy
JF - International Journal of Clinical Pharmacy
IS - 2
ER -